You are right.. its all about future earnings.. who cares that they are cash rich waiting for the next cash cow to be approved.. but then again lets hope that mcopax only provides 1c per share because its about the next drug and future goals.. who cares about fda approved biologics
There's plenty of info in the bio history to prove that earnings by themselves mean squat. If Momenta earned one penny or one dollar it would mean nothing to the shareholders.
Generalizations like your above comment are worthless. Obviously valuations of any company are driven by more than just earnings, however, you have to be off your rocker if you think it doesn't matter whether MNTA generates $3+/share or $0.10/share of earnings. Generating significant free cash flow as MNTA is currently doing is very meaningful to every shareholder as it provides a non-dilutive way for MNTA to fuel its future growth while also reducing downside risk by building a war chest. If mL continues to be the sole generic, MNTA's free cash flow will generate very nice gains for current shareholders.
It's all about their future goals, and Momenta normally keeps that info to itself.
Keeps that info to itself? mC FDA approval and signing lucrative partnerships (FOB, M118, etc.) are their future goals.